[過去ﾛｸﾞ] 【4565】そーせいG 508【薬事･食品衛生審議会医薬品第二部会(5/28)】 (664ﾚｽ)
上下前次1-新

---

このｽﾚｯﾄﾞは過去ﾛｸﾞ倉庫に格納されています｡
次ｽﾚ検索 歴削→次ｽﾚ 栞削→次ｽﾚ 過去ﾛｸﾞﾒﾆｭｰ

---

378: 2020/05/29(金)19:04 ID:kpWhJiVR0NIKU(10/12) AAS
Treatment was associated with a reduction in both the number of immature immune suppressor cells as well as genetic markers of immune suppression in patient samples.
These biomarker data validate the mechanism of action of MTL‑CEBPA in reducing immune suppression, which has been identified as a resistance mechanism of solid tumours to cancer treatment, including sorafenib.
These encouraging Phase Ib data add to the previously published positive Phase I results in which four out of five patients experienced a durable, objective response to off-study sorafenib treatment after discontinuation of MTL‑CEBPA.
As a single agent treatment, sorafenib is associated with a very low objective response rate.
In a recent Phase III study, complete responses were observed in 1% of patients and partial responses were observed in 6% of patients based on RECIST 1.1 criteria in 372 patients1.
The poster will be made available on the “Publications” page of MiNA’s website.
ASCO Presentation information:
Title: Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Abstract no: 4601
Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary
Date / time: Friday, May 29, 2020 / 8:00 am Eastern Time

---

上下前次1-新書関写板覧索設栞歴

---

あと 286 ﾚｽあります
ｽﾚ情報 赤ﾚｽ抽出 画像ﾚｽ抽出 歴の未読ｽﾚ AAｻﾑﾈｲﾙ

---

ぬこの手 ぬこTOP 0.006s